News

Serac Healthcare Partners with University of Oxford to Evaluate the Potential of 99mTc-Maraciclatide to Diagnose Endometriosis Non-Invasively

07/06/2022

Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (⁹⁹ᵐTc-maraciclatide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.

View News Article (PDF)

James McCutcheon FCCA, Appointed Chief Financial Officer

01/11/2021

Please join us in welcoming James to the Serac Healthcare team. James is an experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.

Julie Davis, Appointed Head of Quality Management

01/08/2020

Please join us in welcoming Julie to the Serac Life Sciences team as Head of Quality Management. Julie’s career has been spent in life science and radiopharmaceutical drug discovery, most recently consulting with biotech start-ups including leading the development and implementation of operational processes and quality systems.

Jon Barnett PhD, Appointed Head of CMC and Supply Chain

06/07/2020

We are pleased to announce that Jon has joined Serac Healthcare Limited as Head of CMC and Supply Chain. With over 20 years’ experience on radiopharmaceutical and biopharmaceutical product development and commercial supply, Jon has extensive experience of leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.

Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress 2020

01/06/2020

Results from a Phase II study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the European League Against Rheumatism (“EULAR”) Congress 2020. The oral presentation is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be delivered by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 110

Session: Diagnostics and imaging procedures (Oral Presentations)

View News Article

Druin Burch FRCP, Appointed Chief Scientific Officer (CSO)

01/05/2020

Serac Life Sciences continues to strengthen its management team with the appointment of Dr Druin Burch as Chief Scientific Officer (CSO). Druin is a Consultant Physician at the Oxford University Hospitals NHS Trust, and has three decades experience as a clinician, scientist and writer in the field of developing and testing medical technology.

Abstract for Presentation at the American Congress of Rheumatology (ACR) Congress 2019

07/11/2019

Results from an interim analysis of the first 25 patients enrolled in a study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the American College of Rheumatology (ACR) Congress. The poster is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be presented by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Date: Sunday, November 10, 2019

Session Title: Imaging Of Rheumatic Diseases Poster I

Session Time: 9:00AM-11:00AM

View News Article

Pat Butler, Joins as Board Observer and Advisor.

10/06/2019

Pat, a qualified Chartered Accountant, is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank and was formerly a Senior Director at McKinsey & Co. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.

Serac Healthcare founded to develop a molecular imaging agent to help rheumatologists manage treatment decisions in their patients with rheumatoid arthritis

27/06/2018

Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.

View News Article (PDF)